BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an FDA nod to be used alongside chemotherapy before surgery and as a monotherapy after surgery in certain patients with resectable NSCLC.